News

Plasma Exchange Shows Little Benefit in AAV Treatment, Meta-analysis Finds

Adding plasma exchange to immune-suppressing treatment does not significantly improve clinical outcomes in people with ANCA-associated vasculitis (AAV), a new meta-analysis indicates. The analysis, “The role of plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis,” was published in Clinical Rheumatology. AAV is characterized by…

FDA to Consider Avacopan as Potential Oral Treatment of AAV

The U.S. Food and Drug Administration (FDA) has accepted for review ChemoCentryx‘s application requesting the approval of avacopan to treat ANCA-associated vasculitis (AAV), the company announced in a press release. The agency expects to announce its decision regarding approval on or before July 7, 2021.

AAV Carries High Healthcare Costs, Italian Study Finds

ANCA-associated vasculitis (AAV) carries high healthcare costs for therapies and hospitalizations to treat the disease itself and related infections, a study in Italy has found. The study, “Healthcare and economic burden of ANCA-associated vasculitis in Italy: an integrated analysis from clinical and administrative databases,” was published…

Muscle Biopsies Could Be Useful in AAV Diagnosis, Study Asserts

Muscle biopsies could be used to diagnose ANCA-associated vasculitis (AAV), a new study indicates. The finding suggests that such biopsies are most informative in females or in people with certain inflammation-related conditions. The study, “Muscle biopsy in anti-neutrophil cytoplasmic antibody–associated vasculitis: diagnostic yield depends on anti-neutrophil…